Compare TWO & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TWO | PCRX |
|---|---|---|
| Founded | 2009 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | N/A | 2010 |
| Metric | TWO | PCRX |
|---|---|---|
| Price | $9.52 | $21.99 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $12.94 | ★ $37.60 |
| AVG Volume (30 Days) | ★ 2.7M | 756.7K |
| Earning Date | 01-01-0001 | 05-15-2026 |
| Dividend Yield | ★ 14.88% | N/A |
| EPS Growth | N/A | ★ 107.44 |
| EPS | N/A | ★ 0.16 |
| Revenue | N/A | ★ $541,533,000.00 |
| Revenue This Year | N/A | $9.77 |
| Revenue Next Year | N/A | $9.71 |
| P/E Ratio | ★ N/A | $137.06 |
| Revenue Growth | N/A | ★ 26.04 |
| 52 Week Low | $8.84 | $18.80 |
| 52 Week High | $14.17 | $27.99 |
| Indicator | TWO | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 42.06 | 45.89 |
| Support Level | N/A | $20.09 |
| Resistance Level | $10.25 | $24.65 |
| Average True Range (ATR) | 0.48 | 1.11 |
| MACD | 0.00 | -0.08 |
| Stochastic Oscillator | 36.87 | 37.21 |
Two Harbors Investment Corp is a real estate investment trust focused on investing in, financing, and managing residential mortgage-backed securities, or RMBS; residential mortgage loans; mortgage servicing rights; and commercial real estate. The majority of the company's investment portfolio is split between agency RMBS purchased from government-sponsored enterprises and nonagency RMBS. Two Harbors derives nearly all of its revenue in the form of interest income collected from its investments. The majority of this income is generated by available-for-sale securities, while residential mortgage loans held for investment in securitization trusts also contribute a sizable amount.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.